JPS645006B2 - - Google Patents
Info
- Publication number
- JPS645006B2 JPS645006B2 JP1440880A JP1440880A JPS645006B2 JP S645006 B2 JPS645006 B2 JP S645006B2 JP 1440880 A JP1440880 A JP 1440880A JP 1440880 A JP1440880 A JP 1440880A JP S645006 B2 JPS645006 B2 JP S645006B2
- Authority
- JP
- Japan
- Prior art keywords
- lipid peroxide
- serum
- serum lipid
- dose
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 11
- 238000005502 peroxidation Methods 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 lipid peroxide Chemical class 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1440880A JPS56110618A (en) | 1980-02-08 | 1980-02-08 | Remedy for disease of excess serum lipoperoxide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1440880A JPS56110618A (en) | 1980-02-08 | 1980-02-08 | Remedy for disease of excess serum lipoperoxide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56110618A JPS56110618A (en) | 1981-09-01 |
| JPS645006B2 true JPS645006B2 (cs) | 1989-01-27 |
Family
ID=11860216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1440880A Granted JPS56110618A (en) | 1980-02-08 | 1980-02-08 | Remedy for disease of excess serum lipoperoxide |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56110618A (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
-
1980
- 1980-02-08 JP JP1440880A patent/JPS56110618A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56110618A (en) | 1981-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5690261B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法 | |
| RU2201272C2 (ru) | Применение ингибиторов желудочно-кишечной липазы | |
| JP3926888B2 (ja) | コレステロール低下剤 | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| EA004312B1 (ru) | Применение эйкозапентаеновой и/или докозагексаеновой жирных кислот и/или их этиловых эфиров для приготовления лекарственного средства для снижения уровня смертности пациентов, перенесших инфаркт миокарда | |
| JP3699124B2 (ja) | タイプｉｉ糖尿病のピコリン酸クロム高用量治療 | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| Long et al. | Observations upon the experimental and clinical use of sulphanilamide in the treatment of certain infections | |
| US4068003A (en) | Method of medical treatment of myasthenia | |
| JP2948247B2 (ja) | 高血圧症の治療 | |
| US5416105A (en) | Treating an arteriosclerosis with glimepiride | |
| Morgan et al. | Spontaneous hemoperitoneum from brodifacoum overdose | |
| JPS645006B2 (cs) | ||
| US5272166A (en) | Method for selective reduction of Lp(a) | |
| JPH07103019B2 (ja) | 胃炎治療・予防剤 | |
| EP1437140B1 (en) | Oral pharmaceutical formulation containing active carbon and use of the same | |
| US4068001A (en) | Method of medical treatment of pancreatic insufficiency | |
| JPH01186883A (ja) | 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン | |
| FR2525901A1 (fr) | Agent de prophylaxie et de traitement des anomalies des lipides sanguins et/ou de l'arteriosclerose, a base d'une enzyme proteolytique | |
| JP4628622B2 (ja) | 冠状動脈移植片血管攣縮の治療または予防方法 | |
| US20080160001A1 (en) | Antihypercholesterolemic Formulation with Less Side-Effects | |
| JP4473968B2 (ja) | 血球流動性改善剤 | |
| JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| US6884818B1 (en) | Pharmaceutical compositions containing 8-chloro-3 (β-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxy coumarin base and the salts thereof with cholesterol-lowering activity | |
| Khan et al. | Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee |